Plain-English translation of NCT02981628 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medicine called in children and young adults whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has returned after treatment or is no longer responding to standard therapy. The medication is designed to target and attack leukemia cells that have a specific protein marker called CD22 on their surface. Researchers want to see if this focused approach can help patients reach remission and improve their chances of survival.
When childhood leukemia comes back or stops responding to standard treatment, patients face very serious circumstances and need new options. This medication represents a different approach—instead of using broad chemotherapy, it targets leukemia cells more precisely, which may help reduce side effects while improving results.
Depending on which group you're in, you will receive the medication as an intravenous infusion (through a vein) over about one hour, given on specific days of each treatment cycle. One approach involves receiving the medication alone for up to 6 cycles (about 6 months), while another approach combines it with other chemotherapy medications. Your doctors will monitor how well the treatment is working, check for side effects, and measure minimal residual disease (remaining leukemia cells) through blood and bone marrow tests throughout your participation.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States